relevant clinical studies on prolonged-release melatonin in primary insomnia
Condition
Type of study n Daily melatonin dose
Duration of treatment
Primary insomnia outpatients aged 76 ± 8 (68-93) years who took BZP and had low urinary 6-sulfatoxymelatonin levels randomized, double-blind, placebo-controlled, crossover study 12 2 mg 3 weeks with melatonin or placebo, followed by one-week washout, and then crossed over for another 3 weeks Primary insomnia outpatients aged 79 ± 5.2 (68-93) years under BZP treatment and having low urinary 6-sulfatoxymelatonin levels randomized, double-blind, placebo-controlled, crossover study 21 2 mg 3 weeks with melatonin or placebo, followed by one-week washout, and then crossed over for another 3 weeks Primary insomnia outpatients aged 40-90 years who took BZP and had low urinary 6-sulfatoxymelatonin levels randomized, double-blind, placebo-controlled study followed by a single-blind period 34 2 mg Patients received melatonin or placebo for 6 weeks. They were encouraged to reduce BZP dose 50% during week 2, 75% during weeks 3 and 4, and to discontinue BZP during weeks 5 and 6. Then melatonin was administered (single-blind) for 6 weeks and attempts to discontinue BZP therapy were resumed; follow-up reassessment was performed 6 months later Primary insomnia outpatients aged $55 years Significant improvement in sleep quality and well-being during combined mirtazapine and melatonin intake and during subsequent intake of melatonin alone or together with very low doses of mirtazapine, 5 of 7 women demonstrating weight gain following mirtazapine intake started to reduce weight after melatonin treatment 107 (Continued) submit your manuscript | www.dovepress.com
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Submit your manuscript here: http://www.dovepress.com/chronophysiology-and-therapy-journal ChronoPhysiology and Therapy is an international, peer-reviewed, open access journal focusing on research into the cyclic variations and rhythmicity in physiological processes in the body and the research and development and optimal timing of administration of therapeutic targets to achieve improved outcomes and quality of life for the patient. The manuscript management system is completely online and includes a very quick and fair peer-review system. Body sway tested by the area of the 95% confidence ellipse enclosing the center of pressure (A95) and its path length no effect of melatonin on A95. it increased path length at 4 hours post-dose in open but not closed eyes condition. Zolpidem significantly increased the A95 and path length 109 Discontinuation rate of BZP 31% of patients discontinued BZP after melatonin initiation. The discontinuation rate was higher in patients receiving two or three melatonin prescriptions
